Ceryvyn Therapeutics Ltd. - Unsponsored ADR
CYVNY Healthcare Biotechnology
Ceryvyn Therapeutics Ltd. - Unsponsored ADR’s revenue for fiscal 2025 (year ended June 2025) was $25,000.00, down 80.0% from fiscal 2024.
Follow CYVNY
A Cash Flow Statement is a financial report that details the cash inflows and outflows of a company over a specific period. It is divided into three sections: operating activities, investing activities, and financing activities. This statement helps assess the company’s liquidity, solvency, and overall financial health. By tracking cash movements, it provides insights into the company's ability to generate cash to fund operations, pay debts, and invest in growth. Businesses and investors use it to evaluate the sustainability of a company's cash flow and its financial stability.
| Jun '25 | Dec '24 | Jun '24 | Dec '23 | Older periods | |
|---|---|---|---|---|---|
Net Income |
0.00 | 0.00 | 0.00 | 0.00 |
+7 more TTM periods Free account |
Depreciation & Amortization |
0.00 | — | 0.00 | — | |
Non Cash Items (Other) |
— | (239.89) | — | (185.49) | |
Other operating activities |
(389.10) | (351.06) | (420.27) | (330.59) | |
Operating Cash Flow |
(461.59) | (423.55) | (420.27) | (330.59) | |
Capital expenditures |
(0.06) | (0.07) | (0.07) | (0.05) | |
Net Aquisitions |
0.00 | — | 0.00 | — | |
Investing cash flow |
(0.06) | (0.07) | (0.07) | (0.05) | |
Repayment/Issuance of Debt (Net) |
(0.11) | (0.11) | (0.09) | (0.09) | |
Equity Repurchase (Common, Net) |
— | 171.26 | — | 257.05 | |
Dividends Paid (Total) |
0.00 | — | 0.00 | — | |
Other financial activities |
— | — | 339.00 | — | |
Financing cash flow |
451.65 | 584.17 | 716.59 | 473.04 | |
Exchange Rate Adjustment |
(3.42) | (5.38) | (3.39) | (6.38) | |
Change in Cash |
(13.42) | 155.17 | 292.86 | 136.02 | |
Beginning Cash |
523.32 | 395.48 | 267.64 | 296.64 | |
Ending Cash |
509.90 | 550.65 | 560.50 | 432.66 | |
Dividends Paid (Common) |
0.00 | 0.00 | 0.00 | 0.00 | |
Assets Liabilities Change (Total) |
0.00 | — | 0.00 | — | |
Investments Change (Net) |
0.00 | — | 0.00 | — | |
Issuance/Purchase of Shares |
281.94 | 329.94 | 377.85 | 219.29 |